Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients
AIM: To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact. METHODS: Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital st...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| التنسيق: | article |
| منشور في: |
2010
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/2230 http://dx.doi.org/10.3748/wjg.v16.i8.982 http://www.wjgnet.com/1007-9327/full/v16/i8/982.htm |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513457820270592 |
|---|---|
| author | Nasser, Soumana C. |
| author2 | Dimassi, Hani I. Nassif, Jeanette G. |
| author2_role | author author |
| author_facet | Nasser, Soumana C. Dimassi, Hani I. Nassif, Jeanette G. |
| author_role | author |
| dc.creator.none.fl_str_mv | Nasser, Soumana C. Dimassi, Hani I. Nassif, Jeanette G. |
| dc.date.none.fl_str_mv | 2010-02-28 2015-10-01T10:20:29Z 2015-10-01T10:20:29Z 2015-10-01 |
| dc.identifier.none.fl_str_mv | 1007-9327 http://hdl.handle.net/10725/2230 http://dx.doi.org/10.3748/wjg.v16.i8.982 Nasser, S. C., Nassif, J. G., & Dimassi, H. I. (2010). Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World journal of gastroenterology: WJG, 16(8), 982. http://www.wjgnet.com/1007-9327/full/v16/i8/982.htm |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | World Journal of Gastroenterology |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | AIM: To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact. METHODS: Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital stay in non-intensive care floors. Updated guidelines were used to assess the appropriateness of the indication and route of administration. RESULTS: Complete data collection was available for 286 patients which were used to assess intravenous (IV) PPIs utilization. Around 88% of patients were receiving PPIs for claimed stress ulcer prophylaxis (SUP) indication; of which, only 17% met the guideline criteria for SUP indication, 14% met the criteria for non-steroidal-anti-inflammatory drugs-induced ulcer prophylaxis, while the remaining 69% were identified as having an unjustified indication for PPI use. The initiation of IV PPIs was appropriate in 55% of patients. Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36.7% of these patients were actually switched. The inappropriate initiation of PPIs via the IV route was more likely to take place on the medical floor than the surgical floor (53% vs 36%, P = 0.003). The cost analysis associated with the appropriateness of the indication for PPI use as well as the route of administration of PPI revealed a possible saving of up to $17 732.5 and $14 571, respectively. CONCLUSION: This study highlights the over-utilization of IV PPIs in non-intensive care unit patients. Restriction of IV PPI use for justified indications and route of administration is recommended. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_5876402cbec601bce2202e5e8fe015fa |
| identifier_str_mv | 1007-9327 Nasser, S. C., Nassif, J. G., & Dimassi, H. I. (2010). Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World journal of gastroenterology: WJG, 16(8), 982. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/2230 |
| publishDate | 2010 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patientsNasser, Soumana C.Dimassi, Hani I.Nassif, Jeanette G.AIM: To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact. METHODS: Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital stay in non-intensive care floors. Updated guidelines were used to assess the appropriateness of the indication and route of administration. RESULTS: Complete data collection was available for 286 patients which were used to assess intravenous (IV) PPIs utilization. Around 88% of patients were receiving PPIs for claimed stress ulcer prophylaxis (SUP) indication; of which, only 17% met the guideline criteria for SUP indication, 14% met the criteria for non-steroidal-anti-inflammatory drugs-induced ulcer prophylaxis, while the remaining 69% were identified as having an unjustified indication for PPI use. The initiation of IV PPIs was appropriate in 55% of patients. Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36.7% of these patients were actually switched. The inappropriate initiation of PPIs via the IV route was more likely to take place on the medical floor than the surgical floor (53% vs 36%, P = 0.003). The cost analysis associated with the appropriateness of the indication for PPI use as well as the route of administration of PPI revealed a possible saving of up to $17 732.5 and $14 571, respectively. CONCLUSION: This study highlights the over-utilization of IV PPIs in non-intensive care unit patients. Restriction of IV PPI use for justified indications and route of administration is recommended.PublishedN/A2015-10-01T10:20:29Z2015-10-01T10:20:29Z2010-02-282015-10-01Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1007-9327http://hdl.handle.net/10725/2230http://dx.doi.org/10.3748/wjg.v16.i8.982Nasser, S. C., Nassif, J. G., & Dimassi, H. I. (2010). Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World journal of gastroenterology: WJG, 16(8), 982.http://www.wjgnet.com/1007-9327/full/v16/i8/982.htmenWorld Journal of Gastroenterologyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/22302016-12-01T14:34:21Z |
| spellingShingle | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients Nasser, Soumana C. |
| status_str | publishedVersion |
| title | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| title_full | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| title_fullStr | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| title_full_unstemmed | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| title_short | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| title_sort | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients |
| url | http://hdl.handle.net/10725/2230 http://dx.doi.org/10.3748/wjg.v16.i8.982 http://www.wjgnet.com/1007-9327/full/v16/i8/982.htm |